Cortisol Normalization: The Core Treatment Goal of Cushing’s Syndrome by Xeris (Lunch Product Theater)

Join Xeris Pharmaceuticals® to learn about the primary treatment goal for Cushing's Syndrome: cortisol normalization. Hear about advancements in the long-term management of prolonged exposure to excess cortisol levels and review long-term data associated with the latest treatment option for patients with Cushing’s syndrome. Learn more about lowering cortisol levels to improve clinical signs and symptoms and comorbidity biomarkers. Cortisol normalization increases the quality of life for individuals with Cushing's Syndrome and improves their overall prognosis. This program will review considerations about the treatment journey, the latest recommendations from clinical guidelines, and the importance of individualizing therapy.

This product theater is sponsored by Xeris Pharmaceuticals.